Advicenne announced the reimbursement of Sibnayal (fixed combination of potassium citrate and potassium bicarbonate) in Denmark. Advicenne and FrostPharma, partners for the Nordic and Baltic countries, have achieved a major success with the approved marketing of Sibnayal as of March 1, 2023, by Danish pricing and reimbursement bodies. The Danish authorities recognize that the therapeutic contribution of Sibnayal is commensurate to the severity of the disease in the absence of any treatment alternatives and justifies an annual cost of treatment close to 15,000 euros per patient.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 EUR | -1.75% | -0.59% | -36.84% |
Apr. 08 | Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 25 | Advicenne: ODD designation in cystinuria | CF |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.84% | 22.03M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- ALDVI Stock
- News Advicenne
- Advicenne Announces the Launch of Sibnayal in Denmark